翻译尚未完成，当前显示原文。
(RTTNews) - Equillium, Inc., (EQ), a clinical-stage biotechnology company, reported a wider loss in its third quarter compared to last year, mainly due to higher research & development expenses.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。